Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$52.09 - $64.1 $102,929 - $126,661
-1,976 Reduced 14.26%
11,883 $618,000
Q2 2023

Aug 14, 2023

BUY
$54.67 - $66.44 $757,671 - $920,791
13,859 New
13,859 $877,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $7.85B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Point72 Middle East Fze Portfolio

Follow Point72 Middle East Fze and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Middle East Fze, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Middle East Fze with notifications on news.